

## Deal Corner

January 04, 2019

### RADIANT LIFE TO ACQUIRE MAJORITY STAKE IN MAX HEALTHCARE THROUGH MERGER

#### DEAL BRIEF

Radiant Life Care Private Limited (“**Radiant Life**”), a leading Indian hospital management company promoted by Mr. Abhay Soi and backed by global investment firm KKR announced that its shareholders, through series of transactions, will eventually acquire a majority stake in Max Healthcare Institute Limited (“**Max Healthcare**”) from Max India Limited (“**Max India**”) and South Africa-based hospital operator Life Healthcare.

The deal involves acquisition of 49.7% stake in Max Healthcare from Life Healthcare, and a demerger of the non-healthcare businesses of Max India into a new wholly owned subsidiary of Max India, which will be listed separately. Pursuant to the demerger, Radiant Life will demerge its healthcare business into Max Healthcare followed by reverse merger of the healthcare business of Max India with Max Healthcare (“**Merged Entity**”). The Merged Entity with an equity valuation of INR 72.42 billion (approx. USD 1.03 billion) will be subsequently listed and will operate over 3,200 beds throughout 16 hospitals across India, including tertiary and quaternary care facilities offering high end critical and super speciality care. The Merged Entity will be promoted by Mr. Abhay Soi and co-promoted by KKR, and Mr. Abhay Soi will be the chairman and managing director of the Merged Entity.

Radiant Life is promoted by Mr. Abhay Soi and is in the business of developing/redeveloping hospitals to provide high end quaternary care. Presently, Radiant Life has two iconic facilities in its portfolio namely: BLK Super Specialty Hospital, Delhi and Nanavati Super Specialty Hospital, Mumbai.

Press coverage relation to this transaction is available at [Economic Times](#) and [Live Mint](#).

#### OUR ROLE

We, at [Nishith Desai Associates](#), acted as counsel to Mr. Abhay Soi and Radiant Life and advised on strategic, securities laws, tax and other legal and regulatory aspects of the transaction as well as on the structuring, deal documentation and negotiation.

#### DISCLAIMER

We expressly clarify that this communication is not a solicitation or an invitation of any sort whatsoever from Nishith Desai Associates or any of its members to create an attorney-client relationship. This communication is not intended to be a source of advertising and the recipient should always seek the advice of competent counsel licensed to practice in the recipient's country/state.

This is not a Spam mail. You have received this mail because you have either requested for it or someone must have suggested your name. Since India has no anti-spamming law, we refer to the US directive, which states that a mail cannot be considered Spam if it contains the sender's contact information, which this mail does. In case this mail doesn't concern you, please unsubscribe from mailing list.

## Research Papers

### Fintech

May 05, 2025

### Medical Device Industry in India

April 28, 2025

### Clinical Trials and Biomedical Research in India

April 22, 2025

## Research Articles

### 2025 Watchlist: Life Sciences Sector India

April 04, 2025

### Re-Evaluating Press Note 3 Of 2020: Should India's Land Borders Still Define Foreign Investment Boundaries?

February 04, 2025

### INDIA 2025: The Emerging Powerhouse for Private Equity and M&A Deals

January 15, 2025

## Audio

### CCI's Deal Value Test

February 22, 2025

### Securities Market Regulator's Continued Quest Against “Unfiltered” Financial Advice

December 18, 2024

### Digital Lending - Part 1 - What's New with NBFC P2Ps

November 19, 2024

## NDA Connect

Connect with us at events, conferences and seminars.

## NDA Hotline

[Click here to view Hotline archives.](#)

## Video

### Vyapak Desai speaking on the danger of deepfakes | Legally Speaking with Tarun Nangia | NewsX

April 01, 2025

**SIAC 2025 Rules: Key changes &  
Implications**

February 18, 2025

---